|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005953,
umls-concept:C0011900,
umls-concept:C0026764,
umls-concept:C0030705,
umls-concept:C0032112,
umls-concept:C0205170,
umls-concept:C0205307,
umls-concept:C0220901,
umls-concept:C0231220,
umls-concept:C0546816,
umls-concept:C1515021,
umls-concept:C1609982
|
|
pubmed:issue |
20
|
|
pubmed:dateCreated |
2009-12-7
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Multiparameter flow cytometry immunophenotyping allows discrimination between normal (N-) and myelomatous (MM-) plasma cells (PCs) within the bone marrow plasma cell compartment (BMPCs). Here we report on the prognostic relevance of detecting more than 5% residual normal plasma cells from all bone marrow plasma cells (N-PCs/BMPCs) by multiparameter flow cytometry in a series of 594 newly diagnosed symptomatic MM patients, uniformly treated according to the Grupo Español de MM 2000 (GEM2000) protocol. Our results show that symptomatic MM patients with more than 5% N-PCs/BMPCs (n = 80 of 594; 14%) have a favorable baseline clinical prospect, together with a significantly lower frequency of high-risk cytogenetic abnormalities and higher response rates. Moreover, this group of patients had a significantly longer progression-free survival (median, 54 vs 42 months, P = .001) and overall survival (median, not reached vs 89 months, P = .04) than patients with less than or equal to 5% N-PCs/BMPCs. Our findings support the clinical value of detecting residual normal PCs in MM patients at diagnosis because this reveals a good prognostic category that could benefit from specific therapeutic approaches. This trial was registered at www.clinicaltrials.gov as NCT00560053.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1528-0020
|
|
pubmed:author |
pubmed-author:BladéJoanJ,
pubmed-author:CarreraDoloresD,
pubmed-author:GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la...,
pubmed-author:GalendeJosefinaJ,
pubmed-author:García de CocaAlfonsoA,
pubmed-author:García-BoyeroRaimundoR,
pubmed-author:GonzálezYolandaY,
pubmed-author:GutiérrezNorma CNC,
pubmed-author:HernándezJoseJ,
pubmed-author:López-BergesMaria ConsueloMC,
pubmed-author:LahuertaJuan JoséJJ,
pubmed-author:MartínAlejandroA,
pubmed-author:MartínezRafaelR,
pubmed-author:MateoGemaG,
pubmed-author:MateosMaria VictoriaMV,
pubmed-author:MontalbánMaria AngelesMA,
pubmed-author:MontejanoLauraL,
pubmed-author:OrfaoAlbertoA,
pubmed-author:PérezJose JJJ,
pubmed-author:PaivaBrunoB,
pubmed-author:PalomeraLuisL,
pubmed-author:San-MiguelJesús FJF,
pubmed-author:SuredaAnnaA,
pubmed-author:VidrialesMaria-BelénMB,
pubmed-author:de la RubiaJavierJ,
pubmed-author:de las HerasNataliaN
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
12
|
|
pubmed:volume |
114
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4369-72
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19755674-Adult,
pubmed-meshheading:19755674-Aged,
pubmed-meshheading:19755674-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19755674-Bone Marrow Cells,
pubmed-meshheading:19755674-Disease-Free Survival,
pubmed-meshheading:19755674-Female,
pubmed-meshheading:19755674-Flow Cytometry,
pubmed-meshheading:19755674-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:19755674-Humans,
pubmed-meshheading:19755674-Immunophenotyping,
pubmed-meshheading:19755674-Kaplan-Meier Estimate,
pubmed-meshheading:19755674-Male,
pubmed-meshheading:19755674-Middle Aged,
pubmed-meshheading:19755674-Multiple Myeloma,
pubmed-meshheading:19755674-Plasma Cells,
pubmed-meshheading:19755674-Prognosis
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients.
|
|
pubmed:affiliation |
Hospital Universitario de Salamanca, Salamanca, Spain.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
